

## NC Medicaid and NC Health Choice Pharmacy Prior Approval Request for Hematinics: Procrit/Epogen/Aranesp/Mircera/Retacrit

3. Beneficiary ID #:	1. Beneficiary Last Name:		
	4. Beneficiary Date of Birth:	5. Beneficiary Gender:	
Prescriber Information			
6. Prescribing Provider NPI #:			
7. Requester Contact Informat			
Name:	Phone #:	_Ext	
Drug Information			
8. Drug Name:	9. Strength:	10. Quantity Per 30 Days:	
11. Length of Therapy (in days	s): □ up to 30 Days □ 60 Days □ 90 D	ays □ 120 Days □ 180 Days	
Clinical Information			
<ul><li>□ Drug-to-Drug interaction</li><li>□ Previous episode of an una</li></ul>	e provide reaction : Please list interaction acceptable side effect or therapeutic failure o-morbidity, or unique patient circumstance	x:	
drugs: Age-specific indications: Unique clinical indication sure Unacceptable clinical risk at 1. Is this new therapy? Select 2. What is the diagnosis or the	upported by FDA approval or peer-reviewers associated with therapeutic change: "Yes" for new therapy. Select "No" for contend in the product?	ed literature:	
drugs: Age-specific indications: Unique clinical indication sure Unacceptable clinical risk at 1. Is this new therapy? Select 2. What is the diagnosis or the □ Anemia associated with	upported by FDA approval or peer-reviewer associated with therapeutic change: "Yes" for new therapy. Select "No" for cone indication for the product? renal failure	ed literature:	
drugs: Age-specific indications: Unique clinical indication sure Unacceptable clinical risk at 1. Is this new therapy? Select 2. What is the diagnosis or the	upported by FDA approval or peer-reviewer associated with therapeutic change: "Yes" for new therapy. Select "No" for conte indication for the product? renal failure HIV infection	ed literature:	
drugs:  ☐ Age-specific indications: ☐ Unique clinical indication su ☐ Unacceptable clinical risk a  1. Is this new therapy? Select 2. What is the diagnosis or the ☐ Anemia associated with ☐ Anemia associated with ☐ Anemia associated with	upported by FDA approval or peer-reviewer associated with therapeutic change: "Yes" for new therapy. Select "No" for conte indication for the product? renal failure HIV infection	ed literature:	

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Fax this form to 1-800-678-3189 Pharmacy PA Call Center: 1-866-799-5318